EC
AUTL

EcoR1 Capital’s Autolus Therapeutics AUTL Stock Holding History

EcoR1 Capital’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-69,155
Closed -$859K – 46
2019
Q3 		$859K Buy
+69,155
New +$914K 0.11% 36

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EcoR1 Capital's AUTL Position: Q4 2019 in Review

EcoR1 Capital sold out of Autolus Therapeutics (AUTL) in Q4 2019, closing a stake of 69,155 shares — an estimated $859K sold.

EcoR1 Capital first reported a position in AUTL in Q3 2019 and held it in 1 quarter. The position peaked at $859K in Q3 2019. 55 funds tracked by Wall St. Rank hold AUTL as of Q4 2019.

  • EcoR1 Capital reported no remaining Autolus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • EcoR1 Capital sold 69,155 Autolus Therapeutics shares in Q4 2019, an estimated $859K.
  • EcoR1 Capital first reported a position in Autolus Therapeutics in Q3 2019 and held it in 1 quarter.
  • EcoR1 Capital's Autolus Therapeutics position peaked at $859K in Q3 2019.
  • 55 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2019.

Based on EcoR1 Capital's 13F filing for Q4 2019, filed 14 Feb 2020.